Equities Analysts Offer Predictions for CervoMed Q2 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Equities researchers at Brookline Capital Management boosted their Q2 2025 EPS estimates for shares of CervoMed in a note issued to investors on Tuesday, May 13th. Brookline Capital Management analyst T. Bussian now expects that the company will post earnings of ($0.39) per share for the quarter, up from their previous forecast of ($0.47). Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed’s Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.61) EPS and FY2025 earnings at ($1.91) EPS.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.04. CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The company had revenue of $1.92 million for the quarter, compared to the consensus estimate of $1.70 million.

Several other analysts have also commented on CRVO. Jones Trading raised shares of CervoMed from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Thursday, March 13th. Roth Mkm raised their price target on CervoMed from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, March 18th. Chardan Capital lifted their price objective on shares of CervoMed from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of CervoMed in a report on Tuesday. Finally, Canaccord Genuity Group raised their target price on CervoMed from $12.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.63.

CervoMed Stock Performance

Shares of CRVO opened at $8.32 on Thursday. CervoMed has a one year low of $1.80 and a one year high of $25.67. The firm has a market capitalization of $72.41 million, a price-to-earnings ratio of -4.10 and a beta of -0.23. The stock’s fifty day moving average is $9.02 and its 200-day moving average is $6.46.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CRVO. Rhumbline Advisers boosted its stake in shares of CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after acquiring an additional 1,526 shares during the period. Barclays PLC increased its stake in CervoMed by 323.6% during the 3rd quarter. Barclays PLC now owns 7,748 shares of the company’s stock worth $113,000 after acquiring an additional 5,919 shares during the period. JPMorgan Chase & Co. lifted its position in CervoMed by 251.8% during the fourth quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock worth $34,000 after purchasing an additional 10,352 shares during the period. Virtu Financial LLC acquired a new stake in shares of CervoMed during the 4th quarter worth approximately $26,000. Finally, HighTower Advisors LLC bought a new position in shares of CervoMed in the 1st quarter valued at $104,000. Institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.